2026-08-29T19:27:47Zhttps://repisalud.isciii.es/rest/oai/request

oai:repisalud.isciii.es:20.500.12105/171922024-09-21T09:44:39Zcom_20.500.12105_19604com_20.500.12105_2051col_20.500.12105_19605

00925njm 22002777a 4500 dc Van de Veire, Sara author Stalmans, Ingeborg author Heindryckx, Femke author Oura, Hajimu author Tijeras-Raballand, Annemilaï author Schmidt, Thomas author Loges, Sonja author Albrecht, Imke author Jonckx, Bart author Vinckier, Stefan author Van Steenkiste, Christophe author Tugues, Sònia author Rolny, Charlotte author De Mol, Maria author Dettori, Daniela author Hainaud, Patricia author Coenegrachts, Lieve author Contreres, Jean-Olivier author Van Bergen, Tine author Cuervo, Henar author Xiao, Wei-Hong author Le Henaff, Carole author Buysschaert, Ian author Kharabi Masouleh, Behzad author Geerts, Anja author Schomber, Tibor author Bonnin, Philippe author Lambert, Vincent author Haustraete, Jurgen author Zacchigna, Serena author Rakic, Jean-Marie author Jiménez, Wladimiro author Noël, Agnes author Giacca, Mauro author Colle, Isabelle author Foidart, Jean-Michel author Tobelem, Gerard author Morales-Ruiz, Manuel author Vilar, José author Maxwell, Patrick author Vinores, Stanley A author Carmeliet, Geert author Dewerchin, Mieke author Claesson-Welsh, Lena author Dupuy, Evelyne author Van Vlierberghe, Hans author Christofori, Gerhard author Mazzone, Massimiliano author Detmar, Michael author Collen, Désiré author Carmeliet, Peter author 2010-04-02 Our findings that PlGF is a cancer target and anti-PlGF is useful for anticancer treatment have been challenged by Bais et al. Here we take advantage of carcinogen-induced and transgenic tumor models as well as ocular neovascularization to report further evidence in support of our original findings of PlGF as a promising target for anticancer therapies. We present evidence for the efficacy of additional anti-PlGF antibodies and their ability to phenocopy genetic deficiency or silencing of PlGF in cancer and ocular disease but also show that not all anti-PlGF antibodies are effective. We also provide additional evidence for the specificity of our anti-PlGF antibody and experiments to suggest that anti-PlGF treatment will not be effective for all tumors and why. Further, we show that PlGF blockage inhibits vessel abnormalization rather than density in certain tumors while enhancing VEGF-targeted inhibition in ocular disease. Our findings warrant further testing of anti-PlGF therapies. Cell. 2010 Apr 2;141(1):178-90. 10.1016/j.cell.2010.02.039 1097-4172 Cell 20371353 http://hdl.handle.net/20.500.12105/17192 Further pharmacological and genetic evidence for the efficacy of PlGF inhibition in cancer and eye disease.